SCHEMBL22060520

SCHEMBL22060520

COC1C(OP(O)(=S)OC(C)(C)C)[C@@H](CC(C)(C)C)O[C@H]1n1cnc2c(N)ncnc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.51
ADORA3 P0DMS8 1/20 0.47
RNASEL Q05823 4/20 0.47
DNPH1 O43598 1/20 0.47
PRKAB2 O43741 1/20 0.47
TRPM2 O94759 1/20 0.47
LDHA P00338 1/20 0.47
ADRB2 P07550 1/20 0.47
FBP1 P09467 1/20 0.47
SRC P12931 1/20 0.47
P2RY2 P41231 1/20 0.47
P2RY1 P47900 1/20 0.47
PRKAG1 P54619 1/20 0.47
PRKAA2 P54646 1/20 0.47
PDE4D Q08499 1/20 0.47
KCNH2 Q12809 1/20 0.47
PRKAA1 Q13131 1/20 0.47
PDE3A Q14432 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TAS1R3 Q7RTX0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15280780 1.00 ADORA1 (0.51) ADORA1ADORA3RNASELDNPH1PRKAB2
SCHEMBL19887018 1.00 ADORA1 (0.51) ADORA1ADORA3RNASELDNPH1PRKAB2
SCHEMBL22060530 0.92 ADORA1 (0.55) ADORA1RNASELP2RY1
SCHEMBL15280847 0.92 ADORA1 (0.55) ADORA1RNASELP2RY1
SCHEMBL15280855 0.92 ADORA1 (0.55) ADORA1RNASELP2RY1
SCHEMBL19887049 0.92 ADORA1 (0.51) ADORA1RNASELDNPH1PRKAB2TRPM2
SCHEMBL15280876 0.92 ADORA1 (0.51) ADORA1RNASELDNPH1PRKAB2TRPM2
SCHEMBL15280834 0.91 ADORA1 (0.55) ADORA1ADORA3DNPH1PRKAB2TRPM2
SCHEMBL22292289 0.91 ADORA1 (0.55) ADORA1ADORA3DNPH1PRKAB2TRPM2
SCHEMBL19887061 0.91 ADORA1 (0.55) ADORA1ADORA3DNPH1PRKAB2TRPM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10731159-B2 Cationic lipid DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-08-04 US disclosed
US-20200172903-A1 ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION OSAKA UNIVERSITY (JP) 2020-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200172903-A1 ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION SNCA, ENO1, ENY2 ADORA1 734/4885ADORA3 1219/4885RNASEL 59/4885
US-10731159-B2 Cationic lipid CETP, NPC1L1, LIPA ADORA1 986/4885ADORA3 1475/4885RNASEL 468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.